We are particularly keen to demonstrate our agreement with the Government’s overarching aims for the Mandate to NHS England, as well as its priorities for the health and care system. As the representative body of the bulk of SRH healthcare professionals in the UK, we unreservedly support the prioritisation of preventing ill-health and supporting people to live healthier lives.
The Faculty of Sexual and Reproductive Healthcare (FSRH) welcomes the opportunity to respond to the Advisory Committee on Resource Allocation (ACRA)’s proposed target allocation formula for the 2016/17 public health grant.
The FSRH believes that at present there is a missed opportunity in maternity services. Within these services there is failure to utilise health care professionals to raise the issue of contraception both antenatally and postnatally.
The FSRH welcomes the publication of the new NICE Menopause Guideline in November 2015 which includes 64 recommendations relevant to UK clinical practice.
How effective is 20mcgEE/3mgDRSP as contraception? 20mcgEE/3mg DRSP is of comparable effectiveness to other combined oral contraceptives. [1,2,3] A large US observational study reports lower failure rates amongst users of a 24/4 EE/DRSP regimen than a 21/7 EE/DRSP regimen. The study also suggests greater contraceptive effectiveness of a 24/4 EE/DRSP regimen than with a 24/4 regimen containing EE in combination with norethisterone.
As an organisation focused on sexual and reproductive health – a key component of public health - the FSRH welcomes this review into the efficiency of existing public health indicators. This offers an opportunity to strengthen the PHOF in particular to take into account the sexual and reproductive health of the entire population.
This guidance provides evidence-based recommendations and good practice points for health professionals on the use of barrier methods for contraception and STI prevention. It is intended for any health care professional or health service providing contraception or conception advice in the UK.
Essure® is a form of female sterilisation which involves the hysteroscopic insertion of flexible micro-inserts into the proximal section of the fallopian tubes and is undertaken without general anaesthesia.
A large observational study from the United States found that the risk of unintended pregnancy after Essure sterilisation was similar to that after surgical sterilisation. However just over 2% of women who had Essure sterilisation required a further operation related to the sterilisation procedure within a year.
In its capacity as a specialist SRH organisation, the FSRH welcome the opportunity to outline to the Health Select Committee the challenges that are facing the delivery of contraceptive care in the primary care setting, both in the strict sense of General Practice clinics and the ways in which restrictions on Specialist Contraceptive Services are negatively impacting upon GP workload.
